|
Medical News Receptive Syringe Sharing Among Injection Drug Users in Harlem and the Bronx During the New York State Expanded Syringe Access Demonstration ProgramAugust 22, 2005 Syringe exchange programs (SEP) have been effective in reducing syringe sharing and reuse. To prevent the transmission of blood-borne infections, CDC and other government agencies recommend that injection drug users (IDUs) use a new, sterile syringe for each injection. In order for this recommendation to be implemented fully, drug injectors' access to syringes must be expanded. On January 1, 2001, the New York state Expanded Syringe Access Demonstration Program (ESAP) took effect. The law allows pharmacies to sell up to 10 syringes at a time without a prescription; it also allows syringe distribution through private doctors, hospitals and clinics to persons age 18 or older; and it permits the possession of those syringes for the purpose of injecting drugs. The law requires that providers register with the New York State Department of Health; it mandates an independent evaluation of the program; and it stipulates that the syringes be accompanied by information on safe use and disposal. Researchers in the current study sought to assess changes in receptive syringe sharing since the inception of the ESAP. To accomplish this, they combined data on sociodemographic characteristics and syringe use regarding the last injection episode from three ongoing studies in Harlem and the Bronx from January 2001 through June 2003. These data were analyzed as serial cross sections by 10 calendar quarters. "The increase in the use of pharmacies and other ESAP syringe sources in this sample has been accompanied by a decline in receptive sharing," the researchers concluded. "SEPs remained the most frequent syringe source. This highlights the importance of SEP accessibility for IDUs in Harlem and the Bronx. Further research regarding the potential serious barrier that the cost of syringes may represent for many IDUs is suggested. Increasing SEP access and lowering the cost of syringes at pharmacies may lead to greater reductions in unsafe injecting practices, especially for IDUs with low incomes." Journal of Acquired Immune Deficiency Syndromes 08.01.05; Vol. 39; No. 4: P. 471-477; Enrique R. Pouget, B.A.; Sherry Deren, Ph.D.; Crystal M. Fuller, Ph.D.; Shannon Blaney, M.P.H.; James M. McMahon, Ph.D.; Sun-Yeon Kang, Ph.D.; Stephanie Tortu, Ph.D.; Jonny F. Andia, Ph.D.; Don C. Des Jarlais, Ph.D.; David Vlahov, Ph.D. This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
|